... radiotherapy for patients with diffuse large B cell lymphoma, stages I-IV. The authors queried MEDLINE, EMBASE and the Cochrane Library databases. In addition, they also searched abstracts from ASCO, ASTRO, ASH, ECCO and ESMO from 2000 to 2013 and had a relatively stringent and appropriately defined selection...

.... Chemotherapy 18 F-fluorodeoxyglucose-positron emission tomography Primary bone lymphoma Radiotherapy Primary bone lymphoma (PBL) is a rare disease. PBL comprises less than 1% of all malignant lymphomas, approximately 5% of extranodal non-Hodgkin's lymphomas and 7% of primary bone tumors [ 1 ]. PBL...

...Michael B. Jameson; Stephen O. Evans Chemotherapy Malignancy Radiotherapy Regardless of whether clinicians believe there is any merit to selenium (Se) supplementation in patients with malignancies, it is one of the most common supplements taken by them. The use of Se by cancer...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Hairy cell leukemia Variant Radiotherapy Cladribine Hairy cell leukemia (HCL) is a rare and distinct type of chronic B-cell lymphoproliferative disorder. A variant...

... with early-stage HL compared radiotherapy alone to combined-modality treatment (CMT). It was followed in 1998 by an individual-patient meta-analysis examining the role of radiotherapy with and without chemotherapy. In 2006, a comprehensive meta-analysis focusing on the risk of secondary malignancies...

... described. We report a rare case of an elderly patient with radiotherapy-related BL. A 71-year-old Japanese man, who had a past history of oropharyngeal cancer treated with local irradiation 15 years ago, presented with a left mandibular mass in December 2004. A partial mandibulectomy disclosed pathological...

...J.M. Andrieu; P. Casassus; L. Degos; J.L. Preud’homme; R. Berger; G. Flandrin The occurrence of Burkitt’s lymphoma (BL) following Hodgkin’s disease (HD) has not yet been reported. A patient treated for HD by chemotherapy-radiotherapy association developed a BL 6 years later: it was demonstrated...

... Chemotherapy Hodgkin’s disease Radiotherapy Stage IV Original Papers Acta haemat. 66: 217-225 (1981) Chemotherapy-Radiotherapy versus Chemotherapy in Hodgkin s Disease with Bone Marrow Involvement Retrospective Analysis of 32 Cases1 J. M. Andrieua, P. Cramer», B. Asselainb, N. Teaa, G. Tricotc, G...

..., instructions or products referred to in the content or advertisements. Adult respiratory distress syndrome Drug therapy Myelocytic leukemia Radiotherapy Actahaemat. 77: 180-182(1987) © 1987 S. Karger AG, Basel 0001 -5 7 9 2 /8 7 /0 7 7 3 -0 180 $ 2.75/0 High-Voltage Irradiation and Hydroxyurea...

.... Four types of equations were used to represent and measure the effect of in vitro X-irradiation on lymphocytes from CLL patients and measure the response of patients to a course of radiotherapy. For the in vivo analysis we used data from 10 patients who were routinely treated with a total of 16 courses...

.... Niscea Division of *Radiation Oncology, bHematology-Oncology, and c Pediatric Hematology-Oncology, The New York Hospital-Cornell Medical Center, and Cornell University Medical College, New York, N.Y., USA Key Words. Beta-thalassemia Extramedullary hematopoiesis Radiotherapy Spinal cord compression...

.... Iliopsoas muscle Light chain myeloma Plasmacytoma Quadratus femoris muscle Radiotherapy Systemic amyloidosis Case Reports Acta Haematol 1991;86:40-41 © 1991S. Karger AG, Basel 0001-5792/91/0861-0040 $2.75/0 An Unusual Case of Amyloidosis Complicating Light Chain Myeloma S.I. Handa, T. Sheehan, C.A...

... with ovarian carcinoma receiving platinum-based chemotherapy. Also, r-HuEPO may allow modest dosage increments in chemotherapy or the addition of abdominopelvic radiotherapy. 19 2 2009 © 1992 S. Karger AG, Basel 1992 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

... to 35%; p = 0.07). Major changes have occurred in the BMT protocol: decreasing use of radiotherapy in the conditioning regimen (from 35 to 24%; p < 0.0001) and increasing use of cyclosporin (with or without methotrexate) for GvHD prophylaxis (from 70 to 98%; p < 0.0001). In conclusion, the outcome...